跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
找到 101 条关于
“TLX250-Px”
全部
101
临床试验
33
药物
49
机构
0
资讯
19
4个月前
TLX250-Px Shows Promise for Diagnosing Multiple Kidney Cancer Types Beyond Clear Cell Renal Cell Carcinoma
6个月前
Heidelberg Pharma Secures $45 Million Through Modified Licensing Agreement with HealthCare Royalty and Soleus Capital
6个月前
Heidelberg Pharma Advances Novel ATAC Technology Platform with Multiple Cancer Candidates in Clinical Development
7年前
FDA Issues Complete Response Letter for Telix's Kidney Cancer Imaging Agent TLX250-CDx
10个月前
TLX250-CDx Shows Promise in Triple Negative Breast Cancer as OPALESCENCE Trial Results Published
去年
Telix Pharmaceuticals' TLX250-CDx Enters Phase II Trial for Recurrent Kidney Cancer Detection
去年
Telix Pharmaceuticals' TLX250-CDx Phase III Trial for Kidney Cancer Imaging Doses First Patient in China
2年前
TLX250-CDx Shows High Accuracy in Kidney Cancer Imaging: Phase 3 ZIRCON Trial Published
去年
Telix's TLX250-CDx (Zircaix) BLA for Kidney Cancer Imaging Gains FDA Priority Review
去年
Heidelberg Pharma Secures $20 Million in Amended Royalty Deal with HealthCare Royalty for Renal Cancer Diagnostic
第 1 页,共 2 页
上一页
下一页